Press release 📈 Stocks 🌍 United States

AusperBio Reports 15-Month Functional Cure Durability for AHB-137 in CHB

AusperBio's AHB-137 shows sustained functional cure in chronic hepatitis B patients for up to 15 months post-treatment, bolstering the company's Phase 3 development strategy.

📅 November 6, 2026 🕐 1 min read

1 assets impacted (Forex). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: INR → 3/10 (60% confidence).

📊 Affected Assets (1)

INR

Neutral 🤖 60%

📅 Short-term 🌍 IN · Explicit

AusperBio Reports Sustained Functional Cure up to 15 Months Off All HBV Treatment in Treatment-Naïve and NA-Treated Patients with Chronic Hepatitis B

Catalysts

• Follow-up macroeconomic data releases and central bank policy guidance for INR.

Risk Factors

• Unexpected shifts in inflation or growth data affecting INR rate expectations.

🧭 Full analysis of these assets

🎯 Key Takeaways

AHB-137 maintained functional cure in both treatment-naïve and NA-treated cohorts for up to 15 months off-therapy.
The data supports the potential for AHB-137 to serve as a finite-duration treatment backbone for the 240 million people living with chronic hepatitis B.
AusperBio is currently advancing AHB-137 through a Phase 3 trial in China alongside global development efforts.

📝 Executive Summary

AusperBio Therapeutics announced long-term follow-up data from Study AB-10-8004, demonstrating that its investigational ASO therapy, AHB-137, maintains a functional cure for up to 15 months after treatment cessation. The results, covering both treatment-naïve and NA-treated patients, support the drug's potential as a finite-duration therapy for chronic hepatitis B.

❓ FAQ

What is the significance of the AHB-137 study results?

The study demonstrates that a functional cure for chronic hepatitis B can be sustained after stopping treatment, addressing a major unmet need for finite-duration therapies compared to current lifelong nucleoside analogue (NA) treatments.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article